Trial Profile
A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Cytomegalovirus immune globulin (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 29 Jul 2021 Status changed from active, no longer recruiting to discontinued as per results published in the New England Journal of Medicine
- 29 Jul 2021 Primary endpoint (Composite Outcome) has not been met as per results published in the New England Journal of Medicine
- 29 Jul 2021 Results published in the New England Journal of Medicine